Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TUB-040
- Development stage
- Phase 2
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TUB-040 is a next-generation antibody-drug conjugate (ADC) developed by Tubulis for the treatment of platinum-resistant high-grade ovarian cancer and relapsed/refractory non-small cell lung cancer (NSCLC). It consists of a humanized IgG1 monoclonal antibody targeting NaPi2b, an antigen highly overexpressed in ovarian and lung adenocarcinoma, linked to the topoisomerase I inhibitor exatecan via a cleavable linker using Tubulis’ proprietary P5 conjugation technology. This design enables highly stable, specific tumor targeting with minimal off-target toxicity and durable antitumor responses. TUB-040 has demonstrated superior efficacy in preclinical models compared to other ADCs and is currently being evaluated in phase 1/2a clinical trials. The drug received FDA Fast Track designation for platinum-resistant ovarian cancer.
- Other names
- anti-napi2b/exatecan antibody-drug conjugate tub-040
02
Targets
TOP1 (DNA Topoisomerase I)SLC34A2 (Sodium-dependent phosphate transporter type IIb)
Beyond the preview
Go deeper on TUB-040.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TUB-040.